Adjuvant therapy for cutaneous malignant melanoma.
We discuss the current status of adjuvant therapy for melanoma by first reviewing the rationale and goals of adjuvant therapy and then analyzing the results of published randomized trials. We pay particular attention to adjuvant interferon trials that raise many challenging issues in the management of patients with melanoma at high risk of recurrence. Past adjuvant trials have used immunotherapeutic approaches, chemotherapy, radiation therapy, as well as hormonal and retinoid therapy. We also summarize ongoing adjuvant trials.
Demierre
M F
MF
Department of Dermatology, Medicine, Epidemiology, and Biostatistics, Boston University Schools of Medicine, MA, USA.
Koh
H K
HK
D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012878:Skin Neoplasms / Q000628:therapy*
D007372:Interferons